Regulatory B cells of naive, newly diagnosed and untreated, MS patients express significantly higher levels of SLAMF5 compared to its expression on healthy controls, suggesting a role for SLAMF5 as a negative regulator of Breg levels and activity in the disease. The gene discussed is CD84; the disease is myeloid sarcoma.